These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8590250)

  • 1. Effects of cromakalim and nicorandil on intraocular pressure after topical administration in rabbit eyes.
    Chiang CH; Lin CH
    J Ocul Pharmacol Ther; 1995; 11(3):195-201. PubMed ID: 8590250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Longman SD; Clapham JC; Wilson C; Hamilton TC
    J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of topical natural ergot alkaloids on the intraocular pressure and aqueous humor dynamics in rabbits with alpha-chymotrypsin-induced ocular hypertension.
    Puras G; Santafé J; Segarra J; Garrido M; Melena J
    Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):322-8. PubMed ID: 11981648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nicorandil on cytosolic calcium concentrations and on tension development in the rabbit femoral artery.
    Abe S; Nishimura J; Nakamura M; Kanaide H
    J Pharmacol Exp Ther; 1994 Feb; 268(2):762-71. PubMed ID: 8113988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pinacidil, cromakalim, and nicorandil on potassium currents of rat basilar artery smooth muscle.
    Zhang H; Stockbridge N; Weir B
    Adv Exp Med Biol; 1991; 304():531-41. PubMed ID: 1839488
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of cromakalim, pinacidil and nicorandil on cardiac refractoriness and arterial pressure in open-chest dogs.
    Spinelli W; Follmer C; Parsons R; Colatsky T
    Eur J Pharmacol; 1990 Apr; 179(3):243-52. PubMed ID: 2142089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of topical natural ergot alkaloids on the intraocular pressure and aqueous humor dynamics in oclular normotensive and alpha-chymotrypsin-induced ocular hypertensive rabbits.
    Puras G; Santafé J; Segarra J; Garrido M; Melena J
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1559-67. PubMed ID: 17505840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Potassium channel activators. Perspectives in the treatment of arterial hypertension].
    Giudicelli JF; Richer C; Berdeaux A
    Presse Med; 1991 Jan; 20(2):75-81. PubMed ID: 1825708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits.
    Inoue T; Yokoyoma T; Mori Y; Sasaki Y; Hosokawa T; Yanagisawa H; Koike H
    Curr Eye Res; 2001 Aug; 23(2):133-8. PubMed ID: 11840352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
    Cavero I; Pratz J; Mondot S
    Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K+ channel-opening action contributes to the preventive effects of nicorandil on U46619-induced vasoconstriction of canine large coronary arteries in vivo.
    Kamijo T; Iwai T; Haruta K; Takeda K
    Arch Int Pharmacodyn Ther; 1996; 331(3):273-84. PubMed ID: 9124999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats.
    Pratz J; Mondot S; Montier F; Cavero I
    J Pharmacol Exp Ther; 1991 Jul; 258(1):216-22. PubMed ID: 1906538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.
    Roy Chowdhury U; Rinkoski TA; Bahler CK; Millar JC; Bertrand JA; Holman BH; Sherwood JM; Overby DR; Stoltz KL; Dosa PI; Fautsch MP
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5731-5742. PubMed ID: 29114841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity of action of the novel antihypertensive agent, BRL 34915, as a potassium channel activator. Comparison with nicorandil.
    Coldwell MC; Howlett DR
    Biochem Pharmacol; 1987 Nov; 36(21):3663-9. PubMed ID: 2445348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential.
    Longman SD; Hamilton TC
    Med Res Rev; 1992 Mar; 12(2):73-148. PubMed ID: 1535674
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of K-channel openers on the contractility and electrical activity of antral circular muscle in guinea-pig stomach.
    Kim KW; Kim SJ; Jun JY
    J Smooth Muscle Res; 1993 Oct; 29(5):145. PubMed ID: 8167416
    [No Abstract]   [Full Text] [Related]  

  • 17. Aqueous humor dynamics in alpha-chymotrypsin-induced ocular hypertensive rabbits.
    Melena J; Santafé J; Segarra-Doménech J; Puras G
    J Ocul Pharmacol Ther; 1999 Feb; 15(1):19-27. PubMed ID: 10048344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical application of a cyclic GMP analog lowers IOP in normal and ocular hypertensive rabbits.
    Stein PJ; Clack JW
    Invest Ophthalmol Vis Sci; 1994 May; 35(6):2765-8. PubMed ID: 8188470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
    Satoh K
    Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advance in pharmacology of potassium channels in cardiovascular system and their clinical use].
    Wu Y; Fang D
    Zhonghua Yi Xue Za Zhi; 1992 Mar; 72(3):180-3. PubMed ID: 1319810
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.